Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3081% below fair value
$4.09+0.06 (+1.49%)
Close on Nov 13, 2026Market cap $809.20MP/E 3.7Yield –
Arbutus Biopharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Arbutus Biopharma's operating cash flow for the twelve months ending Sep 30, 2026 was $221.00M. For fiscal 2025 it was -$39.64M. The highest annual figure on record is $32.91M in fiscal 2012.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$39.64M | – |
| FY2024 | Dec 31, 2024 | -$64.85M | – |
| FY2023 | Dec 31, 2023 | -$85.94M | – |
| FY2022 | Dec 31, 2022 | -$35.36M | – |
| FY2021 | Dec 31, 2021 | -$67.53M | – |
| FY2020 | Dec 31, 2020 | -$51.44M | – |
| FY2019 | Dec 31, 2019 | -$71.01M | – |
| FY2018 | Dec 31, 2018 | -$67.87M | – |
| FY2017 | Dec 31, 2017 | -$48.64M | – |
| FY2016 | Dec 31, 2016 | -$57.89M | – |
| FY2015 | Dec 31, 2015 | -$56.38M | – |
| FY2014 | Dec 31, 2014 | -$12.42M | – |
| FY2013 | Dec 31, 2013 | -$6.74M | -120.5% |
| FY2012 | Dec 31, 2012 | $32.91M | – |
| FY2011 | Dec 31, 2011 | -$7.83M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $239.81M | – |
| Q2 FY2026 | Jun 30, 2026 | -$6.02M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.11M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.68M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.82M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.32M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.74M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.30M | -232.4% |
| Q4 FY2022 | Dec 31, 2022 | -$16.99M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.69M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.29M | – |
| Q1 FY2022 | Mar 31, 2022 | $20.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.61M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.04M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.88M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.01M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.17M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.45M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.35M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.47M | – |
| Q2 FY2019 | Jun 30, 2019 | -$17.61M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.58M | – |
| Q4 FY2018 | Dec 31, 2018 | -$17.08M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.20M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.62M | – |
| Q1 FY2018 | Mar 31, 2018 | -$19.97M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.34M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.68M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.08M | – |
| Q1 FY2017 | Mar 31, 2017 | -$17.54M | – |
| Q4 FY2016 | Dec 31, 2016 | -$14.82M | – |
See a number that looks wrong?